Myeloproliferative Neoplasms News

SAN DIEGO — Lower platelet count was identified as a significant predictor for ruxolitinib-induced moderate or severe thrombocytopenia in patients with myelofibrosis, according to research presented at ASH Annual Meeting and Exposition.

SAN DIEGO — The BET inhibitor BMS986158 has continued to be well tolerated in combination with ruxolitinib and fedratinib in patients with intermediate- or high-risk myelofibrosis, according to a study presented at ASH Annual Meeting.

In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting.

SAN DIEGO — Treatment with fedratinib led to “superior” spleen volume reduction and symptom response rates in patients with myelofibrosis previously treated with ruxolitinib, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Researchers found JAK-STAT mutations in a predominance of a cohort of adults with fusion-free hypereosinophilia with features suggesting myeloid neoplasms, according to data presented at ASH Annual Meeting and Exposition.